Search for drugs that improve limb function after synovial sarcoma using the characteristics of tumor cells

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K11252
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 59010:Rehabilitation science-related
• Research Institution: Tokoha University
• Principal Investigator: OHTA Tsutomu 常葉大学, 保健医療学部, 教授 (10290892)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 滑膜肉腫

Outline of Final Research Achievements

Synovial sarcoma is a malignant tumor that accounts for approximately 10% of all soft tissue sarcomas, and its treatment is often limb-salvage surgery, in which the tumor and some healthy tissue are removed. In addition to improving patients' activities of daily living (ADL) and quality of life (QOL), post-surgery rehabilitation is increasingly aimed at reintegrating patients into society. Postoperative recovery of affected limb function, which affects the effectiveness of rehabilitation, largely depends on the tumor shrinkage effect of preoperative anticancer drugs, but no effective anticancer drugs have been found for synovial sarcoma. Therefore, in this study, we searched for effective drugs against synovial sarcoma. As a result, I found that drugs that cut single-stranded DNA or double-stranded DNA suppressed the proliferation of synovial sarcoma cells.

Free Research Field

医学

Academic Significance and Societal Importance of the Research Achievements

本研究によって、既存の抗がん剤の中から滑膜肉腫の細胞増殖能を抑制する（滑膜肉腫を縮小化する）効果的な抗がん剤を見出すことができると考えている。滑膜肉腫を縮小化する効果的な抗がん剤が見つかれば、滑膜肉腫の手術時に切除する組織の量を減らすことになり、手術後の患肢機能回復を促進することが期待される。